Skip to main content

Table 3 Hematologic and Non-Hematologic Adverse Events Related to Ezatiostat in ≥ 5% of Patients

From: Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra®, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome

For All Dose Groups Combined Maximum Toxicity Grade (N = 54)
Adverse Event
(Preferred Term)
Grade 1
n (%)
Grade 2
n (%)
Grade 3
n (%)
Grade 4
n (%)
All Grades
n (%)
Hematologic      
   Anemia 0 (0) 0 (0) 1 (2) 1 (2) 2 (4)
   Leukocytosis 0 (0) 1 (2) 0 (0) 0 (0) 1 (2)
   Leukopenia 0 (0) 0 (0) 1 (2) 0 (0) 1 (2)
   Thrombocytopenia 0 (0) 1 (2) 0 (0) 0 (0) 1 (2)
Non-hematologic      
   Chills 6 (11) 5 (9) 0 (0) 0 (0) 11 (20)
   Back Pain 8 (15) 1 (2) 0 (0) 1 (2) 10 (19)
   Drug Hypersensitivity 4 (7) 1 (2) 3 (6) 2 (4) 10 (19)
   Flushing 10 (19) 0 (0) 0 (0) 0 (0) 10 (19)
   Nausea 8 (15) 0 (0) 1 (2) 0 (0) 9 (17)
   Bone Pain 3 (6) 3 (6) 2 (4) 0 (0) 8 (15)
   Dyspnea 5 (9) 2 (4) 0 (0) 0 (0) 7 (13)
   Fatigue 0 (0) 7 (13) 0 (0) 0 (0) 7 (13)
   Pain in Extremity 4 (7) 2 (4) 1 (2) 0 (0) 7 (13)
   Diarrhea 4 (7) 2 (4) 0 (0) 0 (0) 6 (11)
   Chest Pain 2 (4) 1 (2) 2 (4) 0 (0) 5 (9)
   Dizziness 4 (7) 0 (0) 1 (2) 0 (0) 5 (9)
   Chest Discomfort 3 (6) 1 (2) 0 (0) 0 (0) 4 (7)
   Headache 3 (6) 1 (2) 0 (0) 0 (0) 4 (7)
   Vomiting 4 (7) 0 (0) 0 (0) 0 (0) 4 (7)
   Abdominal Pain Upper 2 (4) 1 (2) 0 (0) 0 (0) 3 (6)
   Arthralgia 2 (4) 1 (2) 0 (0) 0 (0) 3 (6)
   Musculoskeletal Discomfort 3 (6) 0 (0) 0 (0) 0 (0) 3 (6)
   Insomnia 2 (4) 1 (2) 0 (0) 0 (0) 3 (6)